Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Quantum technology company Archer Materials Limited has developed an early Biochip prototype...

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...

Content from other channels on our network

Antimicrobial resistance in Aussie raw retail meats remains low, FSANZ survey finds

What is permissible indulgence, and what does it mean for us in 2026?

What's new on the supermarket shelves in 2026

Large-scale solar for Cargill's oilseed processing plant in NSW

foodpro 2026 now open for registrations

A matter of influence: getting over the 'ick' with recycled water

How sustainability is shaping network strategy

Upcycled mattresses to become sustainable insulation

Study finds the most effective global climate policies

UV used to make recyclable, sustainable polymers

How do different types of pain influence empathy?

St Vincent's Hospital Sydney junior doctors class action underway

Hospital waiting times remain high, new Productivity Commission data reveals

From vision to vigilance: building a secure digital future for health care

The Emergency Department Access & Performance Conference